You're right. I wrote a bad response at midnight. I meant to say something more narrow and specific: genomic assessments and new biomarker tests will become affordable and add information.

For example, single nucleotide polymorphisms. This way doctors spend less time guessing which medication is likely to work best for you when there are many options available.